More physiologically relevant immuno-oncology reporter assays are urgently needed for better modeling of the in vivo immune response to cancer, such as CD8+ cytotoxic T cell-mediated cancer cell killing events, and for immuno-oncology drug discovery and development. This evidence concerns the gene CD8A and cancer.